-DOCSTART- -X- O
Bacteriophage -X- _ O
( -X- _ O
phage -X- _ O
) -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
viruses -X- _ O
that -X- _ O
infect -X- _ O
bacteria -X- _ O
only -X- _ O
, -X- _ O
have -X- _ O
shown -X- _ O
promise -X- _ O
as -X- _ O
vehicles -X- _ O
for -X- _ O
targeted -X- _ O
cancer -X- _ O
gene -X- _ O
therapy -X- _ O
, -X- _ O
albeit -X- _ O
with -X- _ O
poor -X- _ O
efficiency. -X- _ O
Recently -X- _ O
, -X- _ O
we -X- _ O
generated -X- _ O
an -X- _ O
improved -X- _ O
version -X- _ O
of -X- _ O
phage -X- _ O
vectors -X- _ O
by -X- _ O
incorporating -X- _ O
cis -X- _ O
genetic -X- _ O
elements -X- _ O
of -X- _ O
adeno‐associated -X- _ O
virus -X- _ O
( -X- _ O
AAV -X- _ O
) -X- _ O
. -X- _ O
This -X- _ O
novel -X- _ O
AAV -X- _ O
/ -X- _ O
phage -X- _ O
hybrid -X- _ O
( -X- _ O
AAVP -X- _ O
) -X- _ O
efficiently -X- _ O
delivered -X- _ O
systemically -X- _ O
administered -X- _ O
therapeutic -X- _ O
genes -X- _ O
to -X- _ O
various -X- _ O
tumor -X- _ O
targets -X- _ O
by -X- _ O
displaying -X- _ O
an -X- _ O
integrin -X- _ O
tumor‐targeting -X- _ O
ligand -X- _ O
on -X- _ O
the -X- _ O
phage -X- _ O
capsid. -X- _ O
However -X- _ O
, -X- _ O
inherent -X- _ O
limitations -X- _ O
in -X- _ O
bacteriophage -X- _ O
mean -X- _ O
that -X- _ O
these -X- _ O
AAVP -X- _ O
vectors -X- _ O
still -X- _ O
need -X- _ O
to -X- _ O
be -X- _ O
improved. -X- _ O
One -X- _ O
of -X- _ O
the -X- _ O
limitations -X- _ O
of -X- _ O
AAVP -X- _ O
in -X- _ O
mammalian -X- _ O
cells -X- _ O
may -X- _ O
be -X- _ O
its -X- _ O
susceptibility -X- _ O
to -X- _ O
proteasomal -X- _ O
degradation. -X- _ O
The -X- _ O
proteasome -X- _ O
is -X- _ O
upregulated -X- _ O
in -X- _ O
cancer -X- _ B-Patient
and -X- _ O
it -X- _ O
is -X- _ O
known -X- _ O
that -X- _ O
it -X- _ O
constitutes -X- _ O
a -X- _ O
barrier -X- _ O
to -X- _ O
gene -X- _ O
delivery -X- _ O
by -X- _ O
certain -X- _ O
eukaryotic -X- _ O
viruses. -X- _ O
We -X- _ O
report -X- _ O
here -X- _ O
that -X- _ O
inhibition -X- _ B-Outcome
of -X- _ I-Outcome
proteasome -X- _ I-Outcome
improved -X- _ I-Outcome
targeted -X- _ I-Outcome
reporter -X- _ I-Outcome
gene -X- _ I-Outcome
delivery -X- _ I-Outcome
by -X- _ I-Outcome
AAVP -X- _ I-Outcome
in -X- _ I-Outcome
cancer -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
tumors -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
after -X- _ I-Outcome
intravenous -X- _ I-Outcome
vector -X- _ I-Outcome
administration -X- _ I-Outcome
to -X- _ I-Outcome
tumor‐bearing -X- _ I-Outcome
mice. -X- _ I-Outcome
We -X- _ O
also -X- _ O
show -X- _ O
enhanced -X- _ B-Outcome
targeted -X- _ I-Outcome
tumor -X- _ I-Outcome
cell -X- _ I-Outcome
killing -X- _ I-Outcome
by -X- _ I-Outcome
AAVP -X- _ I-Outcome
upon -X- _ I-Outcome
proteasome -X- _ I-Outcome
inhibition. -X- _ I-Outcome
The -X- _ O
AAVP -X- _ B-Outcome
particles -X- _ I-Outcome
persisted -X- _ I-Outcome
significantly -X- _ I-Outcome
in -X- _ I-Outcome
cancer -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
tumors -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
after -X- _ I-Outcome
systemic -X- _ I-Outcome
administration -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
accumulated -X- _ I-Outcome
polyubiquitinated -X- _ I-Outcome
coat -X- _ I-Outcome
proteins. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
proteasome -X- _ B-Outcome
is -X- _ I-Outcome
indeed -X- _ I-Outcome
a -X- _ I-Outcome
barrier -X- _ I-Outcome
to -X- _ I-Outcome
tumor -X- _ I-Outcome
targeting -X- _ I-Outcome
by -X- _ I-Outcome
AAVP -X- _ I-Outcome
and -X- _ O
indicate -X- _ O
that -X- _ O
a -X- _ O
combination -X- _ O
of -X- _ O
proteasome‐ -X- _ O
inhibiting -X- _ O
drugs -X- _ O
and -X- _ O
AAVP -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
for -X- _ O
clinical -X- _ O
anticancer -X- _ O
therapy -X- _ O
. -X- _ O

